KIT and mast cell neoplasm: In their meta-analysis review paper, Coehlo and colleagues pointed out that, among dogs treated with TKIs, 257 dogs received the treatment under the label; 261 received the drug off-label; and 87 dogs received masitinib due to the presence of non-resectable mast cell tumors (grade II or III) with confirmed mutated KIT [133].